Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

There is a large global unmet need for the development of countermeasures to combat
hundreds of viruses known to cause human disease and for the establishment of a …

Cellular lipid membranes serve as the primary barrier preventing viral infection of the host
cell and provide viruses with a critical initial point of contact. Occasionally, viruses can utilize …

COVID-19 infections decrease total cholesterol, LDL-C, HDL-C, and apolipoprotein AI, A-II,
and B levels while triglyceride levels may be increased or inappropriately normal for the …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL)
uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated …

Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged
as a novel class of drugs with cardioprotective effects through their lipid‐lowering effects …

Cardiovascular diseases (CVDs) are the leading cause of death among elderly people.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of …

Background Many commonly used drugs were evaluated as repurposed treatment options
since the emergence of the COVID-19 pandemic. The benefit of lipid-lowering agents has …

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a well-known regulator of cholesterol
metabolism and cardiovascular diseases, has recently garnered attention for its emerging …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the major regulators of low-
density lipoprotein receptor (LDLR). Information on role and regulation of PCSK9 in lung is …